Ratio Therapeutics https://validator.w3.org/feed/docs/rss2.html Our Technology Blog Our Pipeline Homepage Ratio Therapeutics has successfully dosed the first cohort in its Phase 1/2 study evaluating a novel FAP-targeted radiopharmaceutical in patients with late-stage aggressive sarcomas Ratio Therapeutics Announces the Appointment of Marcel Reichen as Chief Strategy Officer Press Release – Ratio Therapeutics Launches Media Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer The Team June 17th, 2025: Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals March 12th, 2024: Ratio Announces Expansion of Manufacturing Agreement with PharmaLogic for FAP-Targeted Radiopharmaceuticals April 2nd, 2024: Ratio Strengthens its Leadership Team with the Appointments of Bill Cupelo as Chief Business Officer and D. Scott Holbrook to its Board of Directors June 20th, 2024: Ratio Therapeutics Announces the Appointment of Former Senator William Cowan to its Board of Directors May 8th, 2025: Ratio Therapeutics to Establish New Radiopharmaceutical Manufacturing Facility Careers PR – Noel Monks Ratio Therapeutics Head of Biology PR – Ratio Therapeutics Series A November 18th, 2024: Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate May 6th, 2024: Ratio Therapeutics Announces the Appointment of Marc Becker as Chief Financial Officer and Chief Operating Officer June 13, 2025: Ratio Therapeutics Partners with Macrocyclics for Exclusive Manufacturing and Distribution of its Radiopharmaceutical Chelator Platform June 10th, 2022: Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers December 6th, 2022: Ratio Therapeutics Appoints Reed Malleck as Chief Financial Officer Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted Radiotherapeutics January 17th, 2024: Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment Homepage News PR – Ratio Merck License Agreement Contact Us Press Release – Phase I Novel FAP-Targeted Radiopharmaceutical Press Release – Ratio Therapeutics Announces Opening of New Research and Development Facility February 1st, 2023: Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment March 13th, 2023: Ratio Therapeutics Appoints Dr. Noel Monks as Head of Biology March 28th, 2023: Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck May 9th, 2023: Ratio Therapeutics Announces Opening of New Research and Development Facility July 11th, 2023: Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging News PR – E & Z Ratio Joint Development July 6th, 2022: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225 PR – Jacob Hesterman Ratio Therapeutics Chief Data Officer PR – Reed Malleck Ratio Therapeutics Chief Financial Officer September 15th, 2022: Ratio Therapeutics Appoints Jacob Hesterman, Ph.D., as Chief Data Officer